Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2012. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the vesting and tax-related sales of shares under the 2009 Performance Share Plan.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation transactions and does not contain consolidated financial statements or key performance indicators for the period.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details the partial vesting (49%) of conditional share awards granted in 2009 following a three-year performance period approved on February 17, 2012.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It strictly reports on the sale of Ordinary Shares and the withholding of American Depositary Shares (ADS) on March 8, 2012, to meet tax liabilities associated with the vested awards.
Key Facts for Investor Verification
- Transaction Date: March 8, 2012 (notification date March 9, 2012).
- Share Prices: Ordinary Shares sold at £14.20; ADS withheld at $44.55.
- Executive Activity: Sir Andrew Witty (Executive Director) sold 2,486 Ordinary Shares; Dr. M M Slaoui (Executive Director) had 281 ADS withheld.
- Plan Details: Transactions relate to the 2009 Performance Share Plan with a 49% vesting rate.
- Financial Data: No financial performance data is included in this specific filing.